ArticleEuropean journal of pediatrics2026
Admission inflammatory biomarker phenotypes and risk of severe community-acquired pneumonia and PARDS in young children.
Article in European journal of pediatrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Advanced cytokine-based frameworks for pediatric acute respiratory distress syndrome (PARDS) are not readily applicable in routine practice. We investigated whether routinely available admission biomarkers could define inflammatory phenotypes in young children hospitalized with community-acquired pneumonia (CAP) and provide prognostic information for severe CAP and in-hospital PARDS, with potential relevance for resource-constrained settings. In this prospective cohort of children aged < 5 years hospitalized with CAP, seven admission biomarkers (neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, lymphocyte-to-monocyte ratio, systemic immune-inflammation index, systemic inflammation response index, C-reactive protein, and procalcitonin) were log1p-transformed, standardized, and analyzed using K-means clustering. Associations with severe CAP at admission and definite in-hospital PARDS were examined using age- and sex-adjusted logistic regression. Incremental prognostic performance was evaluated using nested models, receiver operating characteristic analysis, calibration, and decision curve analysis. Among 129 children, three biomarker phenotypes were identified: low-inflammatory (n = 40), intermediate-inflammatory (n = 60), and hyper-inflammatory (n = 29). Compared with the low-inflammatory phenotype, adjusted odds of PARDS were higher in the intermediate-inflammatory (OR 4.00, 95% CI 1.17-18.6; p = 0.043) and hyper-inflammatory phenotypes (OR 11.6, 95% CI 2.90-60.9; p = 0.001). Only the hyper-inflammatory phenotype was independently associated with severe CAP at admission (OR 4.79, 95% CI 1.54-16.2; p = 0.009). Adding biomarker phenotype to age and sex improved PARDS discrimination (AUC 0.571 to 0.716), but discrimination was similar to NLR alone (AUC 0.711), and gain beyond severe CAP was modest.
conclusionsRoutine admission biomarkers identified inflammatory phenotypes associated with severe CAP and PARDS. This low-cost may be relevant in resource-constrained settings but requires external validation. WHAT IS KNOWN: • Hyperinflammatory biology is associated with worse outcomes in pediatric CAP and PARDS, but most biomarker frameworks rely on research-oriented cytokine panels. • Routine admission biomarkers such as CRP, PCT, and CBC-derived indices are widely available, but their value for inflammatory phenotyping remains unclear. WHAT IS NEW: • Routine admission biomarkers identified three clinically interpretable inflammatory phenotypes in young children hospitalized with CAP. • The hyper-inflammatory phenotype was associated with severe CAP and PARDS; this pragmatic approach may be relevant in resource-constrained settings, although discrimination was similar to NLR alone.
Indexed as
Identifiers
42570118What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.